Dry AMD trial doses first patient

Article

US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).

US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).

The trial, to determine safety, tolerability and pharmacokinetics of the oral treatment, is a single-site, double-masked, placebo-controlled, single ascending-dose study treating healthy subjects.

ACU-02 reduces the accumulation of A2E, thereby interrupting the pathophysiology of AMD and preserving retinal cells.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.